Plain-English Summary
SURMOUNT-4 is the tirzepatide maintenance counterpart to STEP 4: people who kept treatment generally maintained or extended weight loss, while those switched to placebo regained weight on average.
Key Findings
- Participants lost substantial weight during the open-label tirzepatide lead-in before randomization.
- Continuing tirzepatide after the lead-in produced further average weight loss, while switching to placebo led to average weight regain.
- Most participants who continued tirzepatide maintained a large share of their prior weight loss, while most switched to placebo did not.
- The trial strongly supports the chronic-treatment framing for maintenance in medication responders.
Limitations
- Withdrawal design enriches for participants who tolerated and responded to tirzepatide during the lead-in.
- The study does not prove that every patient must stay on tirzepatide indefinitely.
- The trial does not answer affordability, access, long-term adherence, or off-ramp protocols.
Why It Matters
It gives the site a stronger, drug-class-level way to discuss weight regain after stopping incretin therapy rather than relying only on semaglutide data.
Viral Vitalism Verdict
Excellent maintenance evidence for responders, but not a simplistic forever-drug mandate.